Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 26, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.27 to $2,046,500.00.

Highlighted Stocks Traded by Insiders:

Dyax (DYAX) - FREE Research Report

Christensen Gustav, who is CEO and President at Dyax, sold 18,750 shares at $15.64 on Feb. 26, 2015. Following this transaction, the CEO and President owned 218,750 shares meaning that the stake was reduced by 7.89% with the 18,750-share transaction.

Ashe Andrew D., who is General Counsel & EVP at Dyax, sold 1,500 shares at $15.34 on Feb. 26, 2015. Following this transaction, the General Counsel & EVP owned 36,527 shares meaning that the stake was reduced by 3.94% with the 1,500-share transaction.

The shares most recently traded at $15.12, down $0.22, or 1.46% since the insider transaction. Historical insider transactions for Dyax go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 10,000

The average volume for Dyax has been 973,000 shares per day over the past 30 days. Dyax has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 10.1% year-to-date as of the close of trading on Thursday.

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. Currently, there are 6 analysts who rate Dyax a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DYAX - FREE

TheStreet Quant Ratings

rates Dyax as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and poor profit margins. Get the full

Dyax Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cimarex Energy (XEC) - FREE Research Report

Box Jerry, who is Director at Cimarex Energy, sold 5,000 shares at $113.11 on Feb. 26, 2015. Following this transaction, the Director owned 6,960 shares meaning that the stake was reduced by 41.81% with the 5,000-share transaction.

The shares most recently traded at $109.68, down $3.43, or 3.13% since the insider transaction. Historical insider transactions for Cimarex Energy go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for Cimarex Energy has been 1.6 million shares per day over the past 30 days. Cimarex Energy has a market cap of $10.2 billion and is part of the basic materials sector and energy industry. Shares are up 6.31% year-to-date as of the close of trading on Thursday.

Cimarex Energy Co. operates as an independent oil and gas exploration and production company primarily in Texas, Oklahoma, and New Mexico. The company owns interests in 4,160 net productive oil and gas wells. The stock currently has a dividend yield of 0.55%. The company has a P/E ratio of 20.2. Currently, there are 16 analysts who rate Cimarex Energy a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XEC - FREE

TheStreet Quant Ratings

rates Cimarex Energy as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

Cimarex Energy Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PS Business Parks (PSB) - FREE Research Report

Schultz Peter, who is Director at PS Business Parks, bought 1,210 shares at $82.80 on Feb. 26, 2015. Following this transaction, the Director owned 1,210 shares meaning that the stake was boosted by 100% with the 1,210-share transaction.

The shares most recently traded at $83.33, up $0.53, or 0.64% since the insider transaction. Historical insider transactions for PS Business Parks go as follows:

  • 4-Week # shares bought: 96
  • 12-Week # shares bought: 96
  • 24-Week # shares bought: 96

The average volume for PS Business Parks has been 109,700 shares per day over the past 30 days. PS Business Parks has a market cap of $2.2 billion and is part of the financial sector and real estate industry. Shares are up 2.98% year-to-date as of the close of trading on Thursday.

PS Business Parks, Inc., a real estate investment trust (REIT), together with its subsidiaries, engages in the acquisition, development, ownership, and operation of commercial properties primarily multi-tenant flex, office, and industrial space. The stock currently has a dividend yield of 2.42%. The company has a P/E ratio of 19.7. Currently, there is 1 analyst who rates PS Business Parks a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PSB - FREE

TheStreet Quant Ratings

rates PS Business Parks as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, reasonable valuation levels, impressive record of earnings per share growth, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full

PS Business Parks Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null